166 related articles for article (PubMed ID: 37399010)
21. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.
Lim M; Shulman DS; Roberts H; Li A; Clymer J; Bona K; Al-Sayegh H; Ma C; DuBois SG
Cancer Med; 2020 Sep; 9(18):6658-6666. PubMed ID: 32750219
[TBL] [Abstract][Full Text] [Related]
22. Off-label drug prescribing in a Portuguese paediatric emergency unit.
Ribeiro M; Jorge A; Macedo AF
Int J Clin Pharm; 2013 Feb; 35(1):30-6. PubMed ID: 23054136
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Off-Label and Unlicensed Drug Use and Its Implications.
Gore R; Chugh PK; Tripathi CD; Lhamo Y; Gautam S
Curr Clin Pharmacol; 2017; 12(1):18-25. PubMed ID: 28322168
[TBL] [Abstract][Full Text] [Related]
25. [Off-label and unlicensed drug use: Results from a pilot study in a pediatric intensive care unit].
García-López I; Fuentes-Ríos JE; Manrique-Rodríguez S; M Fernández-Llamazares C
An Pediatr (Barc); 2017 Jan; 86(1):28-36. PubMed ID: 27151379
[TBL] [Abstract][Full Text] [Related]
26. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.
Joerger M; Schaer-Thuer C; Koeberle D; Matter-Walstra K; Gibbons-Marsico J; Diem S; Thuerlimann B; Cerny T
Eur J Clin Pharmacol; 2014 Jun; 70(6):719-25. PubMed ID: 24609468
[TBL] [Abstract][Full Text] [Related]
27. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).
Penel-Page M; Ray-Coquard I; Larcade J; Girodet M; Bouclier L; Rogasik M; Corradini N; Entz-Werle N; Brugieres L; Domont J; Lervat C; Piperno-Neumann S; Pacquement H; Bay JO; Gentet JC; Thyss A; Chaigneau L; Narciso B; Cornille H; Blay JY; Marec-Bérard P
BMC Cancer; 2015 Nov; 15():854. PubMed ID: 26541413
[TBL] [Abstract][Full Text] [Related]
28. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.
Eguale T; Buckeridge DL; Verma A; Winslade NE; Benedetti A; Hanley JA; Tamblyn R
JAMA Intern Med; 2016 Jan; 176(1):55-63. PubMed ID: 26523731
[TBL] [Abstract][Full Text] [Related]
29. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
30. Off-label prescribing in pediatric outpatients.
Palmaro A; Bissuel R; Renaud N; Durrieu G; Escourrou B; Oustric S; Montastruc JL; Lapeyre-Mestre M
Pediatrics; 2015 Jan; 135(1):49-58. PubMed ID: 25511119
[TBL] [Abstract][Full Text] [Related]
31. Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol.
Nguyen KA; Mimouni Y; Jaberi E; Paret N; Boussaha I; Vial T; Jacqz-Aigrain E; Alberti C; Guittard L; Remontet L; Roche L; Bossard N; Kassai B
Therapie; 2021; 76(6):675-685. PubMed ID: 33593598
[TBL] [Abstract][Full Text] [Related]
32. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.
Neubert A; Dormann H; Weiss J; Egger T; Criegee-Rieck M; Rascher W; Brune K; Hinz B
Drug Saf; 2004; 27(13):1059-67. PubMed ID: 15471510
[TBL] [Abstract][Full Text] [Related]
33. Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
Dubrall D; Leitzen S; Toni I; Stingl J; Schulz M; Schmid M; Neubert A; Sachs B
BMC Pharmacol Toxicol; 2021 Oct; 22(1):56. PubMed ID: 34620231
[TBL] [Abstract][Full Text] [Related]
34. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
35. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study.
Song H; Zhong CS; Kieran MW; Chi SN; Wright KD; Huang JT
Pediatr Blood Cancer; 2019 Jun; 66(6):e27682. PubMed ID: 30821092
[TBL] [Abstract][Full Text] [Related]
37. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of off-label drug uses in hospitals: a multicentric prospective study.
Danés I; Agustí A; Vallano A; Alerany C; Martínez J; Bosch JA; Ferrer A; Gratacós L; Pérez A; Olmo M; Marron SM; Valderrama A; Bonafont X
Eur J Clin Pharmacol; 2014 Nov; 70(11):1385-93. PubMed ID: 25196202
[TBL] [Abstract][Full Text] [Related]
39. Respiratory drugs prescribed off-label among children in the outpatient clinics of a hospital in Malaysia.
Mohamad NF; Mhd Ali A; Mohamed Shah N
Int J Clin Pharm; 2015 Feb; 37(1):127-32. PubMed ID: 25488318
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Geoerger B; Zwaan CM; Marshall LV; Michon J; Bourdeaut F; Casanova M; Corradini N; Rossato G; Farid-Kapadia M; Shemesh CS; Hutchinson KE; Donaldson F; Liao M; Caron H; Trippett T
Lancet Oncol; 2020 Jan; 21(1):134-144. PubMed ID: 31780255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
